Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Cancer Survival Analysis01:21

Cancer Survival Analysis

787
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
787

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinico-molecular predictors of durable response to immune checkpoint inhibitors (ICI) in metastatic cervical cancer (mCC).

British journal of cancer·2026
Same author

Prediction of Mutations and Outcome in Gastrointestinal Stromal Tumors with Deep Learning: A Multicenter, Multinational Study.

medRxiv : the preprint server for health sciences·2026
Same author

Codon-specific <i>KRAS</i> mutations predict survival in advanced pancreatic cancer.

ESMO gastrointestinal oncology·2026
Same author

Corrigendum to "Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)": [Ann Oncol 26 (2015) 2168-2173].

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Expression of antibody-drug conjugate targets in soft tissue sarcomas.

ESMO open·2025
Same author

BOS172738, a selective RET inhibitor, for the treatment of patients with RET-altered tumors including RET-fusion-positive non-small-cell lung cancer and RET-mutant medullary thyroid cancer: a phase I dose-escalation/expansion multicenter study.

ESMO open·2025

Related Experiment Video

Updated: Feb 19, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

10.4K

Improved survival using specialized multidisciplinary board in sarcoma patients.

J-Y Blay1, P Soibinet2, N Penel3

  • 1Department of Medical and Surgical Oncology, Centre Léon Bérard, Lyon; Department of Université Claude Bernard, Lyon.

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|November 9, 2017
PubMed
Summary

Presenting sarcoma patients to a multidisciplinary tumor board (MDTB) before treatment significantly improves adherence to guidelines and patient outcomes. This nationwide study highlights the crucial role of early specialized management in enhancing sarcoma care and survival rates.

Keywords:
clinical practice guidelinesmultidisciplinarityrelapsesarcomasurvivaltumor board

More Related Videos

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

13.3K
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

15.3K

Related Experiment Videos

Last Updated: Feb 19, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

10.4K
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

13.3K
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

15.3K

Area of Science:

  • Oncology
  • Clinical Management
  • Public Health

Background:

  • Sarcomas are rare, aggressive cancers requiring specialized care.
  • Multidisciplinary tumor board (MDTB) management is not universally implemented.
  • This study evaluates the impact of pre-treatment MDTB presentation on sarcoma patient outcomes.

Purpose of the Study:

  • To investigate the effect of multidisciplinary tumor board (MDTB) presentation before treatment on sarcoma patient management and survival.
  • To assess compliance with clinical practice guidelines in sarcoma care.
  • To analyze the nationwide impact of a specialized sarcoma network.

Main Methods:

  • A nationwide study in France involving 12,528 sarcoma patients (≥15 years) from 2010-2014.
  • Patients were analyzed based on whether they were presented to a multidisciplinary tumor board (MDTB) before or after initial treatment.
  • Data collected through the NETSARC network, including patient characteristics, management, and follow-up.

Main Results:

  • 42.2% of patients were presented to an MDTB before treatment; these patients often had worse prognostic factors.
  • Pre-treatment MDTB presentation correlated with better adherence to guidelines (biopsy, imaging, surgery quality) and fewer reoperations (P < 0.001).
  • Significantly improved local relapse-free survival and relapse-free survival were observed in patients treated after pre-treatment MDTB consultation (univariate and multivariate analysis).

Conclusions:

  • Pre-therapeutic multidisciplinary tumor board (MDTB) guidance significantly enhances sarcoma patient compliance with clinical practice guidelines.
  • Early MDTB involvement leads to improved relapse-free survival for sarcoma patients.
  • Specialized, multidisciplinary management prior to treatment is critical for optimizing sarcoma outcomes.